Guobang Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,512	1,460	1,909	2,094	1,974	893.01
Trading Asset Securities	1,254	1,243	617.66	465.99	824.56	1,258
Cash & Short-Term Investments	2,765	2,703	2,527	2,560	2,799	2,151
Cash Growth	18.55%	6.96%	-1.29%	-8.52%	30.09%	74.24%
Accounts Receivable	1,604	1,394	1,332	964.92	775.34	571.5
Other Receivables	6.78	43.32	67.35	17.22	21.07	45.03
Receivables	1,610	1,438	1,399	982.14	796.41	616.53
Inventory	1,741	1,776	1,363	1,369	1,409	1,309
Prepaid Expenses	-	-	-	-	-	0.7
Other Current Assets	415.48	195.95	584.67	532.31	125.15	489.48
Total Current Assets	6,532	6,113	5,874	5,443	5,129	4,567
Property, Plant & Equipment	4,303	4,289	4,344	4,330	3,284	2,622
Long-Term Investments	116.95	118.71	112.57	121.13	101.37	17.11
Goodwill	0.03	0.03	0.03	0.03	0.03	0.03
Other Intangible Assets	341.69	342.65	350.83	358.85	370.5	272.26
Long-Term Deferred Tax Assets	13.59	13.52	8.96	7.78	6.59	19.02
Long-Term Deferred Charges	6.86	6.98	7.45	8.02	9.26	2.6
Other Long-Term Assets	82.08	100.91	82.64	92.64	142.61	12.79
Total Assets	11,396	10,985	10,780	10,362	9,043	7,513
Accounts Payable	1,466	1,196	1,704	1,715	974.35	789.71
Accrued Expenses	62.03	129.85	125.97	97.06	107.06	100.47
Short-Term Debt	511.07	512.2	181.23	488.79	664.28	168.88
Current Portion of Long-Term Debt	400.32	7.29	452.17	28.88	-	-
Current Income Taxes Payable	52.1	23.75	22.47	18.44	4.26	30.24
Current Unearned Revenue	43.79	25.35	39.93	55.85	52.79	30.68
Other Current Liabilities	35.69	26.53	32.34	45.99	59.64	33.53
Total Current Liabilities	2,571	1,921	2,558	2,450	1,862	1,154
Long-Term Debt	82.88	478.01	146.72	451.7	-	-
Long-Term Unearned Revenue	25.05	25.86	16.67	11.8	14.27	9.71
Long-Term Deferred Tax Liabilities	1.09	3.94	7.2	11.32	11.93	4.16
Total Liabilities	2,680	2,429	2,728	2,924	1,889	1,167
Common Stock	558.82	558.82	558.82	558.82	558.82	558.82
Additional Paid-In Capital	3,627	3,627	3,609	3,607	3,607	3,607
Retained Earnings	4,527	4,367	3,881	3,266	2,989	2,180
Treasury Stock	-	-	-1.48	-	-	-
Total Common Equity	8,714	8,553	8,047	7,432	7,155	6,346
Minority Interest	1.93	2.43	4.72	5.15	-0.65	-0.39
Shareholders' Equity	8,716	8,556	8,052	7,437	7,155	6,346
Total Liabilities & Equity	11,396	10,985	10,780	10,362	9,043	7,513
Total Debt	994.27	997.5	780.12	969.37	664.28	168.88
Net Cash (Debt)	1,771	1,705	1,747	1,591	2,134	1,982
Net Cash Growth	38.43%	-2.37%	9.81%	-25.46%	7.66%	528.79%
Net Cash Per Share	3.21	3.08	3.13	2.86	3.82	3.87
Filing Date Shares Outstanding	553.9	558.82	558.37	555.51	558.82	558.82
Total Common Shares Outstanding	553.9	558.82	558.74	558.82	558.82	558.82
Working Capital	3,961	4,192	3,317	2,994	3,267	3,414
Book Value Per Share	15.73	15.31	14.40	13.30	12.80	11.36
Tangible Book Value	8,372	8,210	7,696	7,073	6,785	6,074
Tangible Book Value Per Share	15.11	14.69	13.77	12.66	12.14	10.87
Buildings	-	1,893	1,812	1,706	1,025	810.75
Machinery	-	4,256	3,980	3,372	2,487	1,933
Construction In Progress	-	282.88	255.26	636.65	874.85	827.46

Source: S&P Global Market Intelligence. Standard template. Financial Sources.